EYPT: LUGANO primary-endpoint failure and the durability evidence

Angiogenesis and treatment duration

DURAVYU combines the kinase inhibitor vorolanib with a bioerodible intravitreal insert. In wet AMD the objective is sustained suppression of pathological vascular leakage while preserving visual acuity. Receptor inhibition differs from extracellular VEGF binding, but a broader mechanism does not automatically improve vision compared with a well-administered anti-VEGF control. [1] [5]

Clinical interpretation: durability is valuable only if reduced injections do not sacrifice vision. Anatomy, visual acuity and treatment burden are related but distinct outcomes. An eye may remain anatomically controlled yet lose vision from another process; a randomized treatment strategy must account for the total patient outcome rather than redefine success around favorable biological components.

Repeated insert dosing and rescue

LUGANO compared DURAVYU 2.7 mg on a six-month repeat schedule with on-label 2 mg aflibercept in a double-masked randomized trial. Both treatment-naïve and previously treated active wet AMD were eligible. The primary assessment averaged change in BCVA at weeks 52 and 56, so the study tested repeat-treatment performance rather than only the first insert's early effect. [1] [5]

Analytical judgment: supplemental aflibercept is part of the treatment strategy, not evidence to discard a participant. The protocol's rescue threshold, number of visits and missing-data handling determine whether a low injection count represents adequate sustained control. Repeat dosing also requires attention to residual insert material, local exposure and cumulative inflammation.

DAVIO2 supported development but did not predict Phase3

DAVIO2 enrolled 160 patients and used two active dose groups plus aflibercept control. Reported BCVA differences at the blended six-month endpoint were −0.3 and −0.4 letters for the originally labeled 2 mg and 3 mg doses. The detailed presentation lists smaller endpoint-specific denominators, including 50, 52 and 54 for injection analyses; these are not interchangeable with total enrollment. [3] [4] [6]

The presentation reported 63% supplement-free at six months for each active dose, while treatment-burden reductions differed depending on whether comparison used prior treatment history or prospective aflibercept. Mixing those comparators creates an exaggerated durability narrative. A short Phase2 noninferiority result does not ensure a longer, repeatedly dosed Phase3 trial will succeed.

LUGANO failed the full-dataset primary endpoint

On August 17, 2026, EyePoint disclosed that LUGANO did not meet its primary noninferiority endpoint in the full dataset. The company highlighted an ad hoc analysis excluding nine of 211 DURAVYU patients with ≥15-letter loss attributed to causes unrelated to wet AMD; that restricted analysis had nominal p=0.0096. These are separate results. [1] [2]

Analytical judgment: unequal vision-loss causes can explain sensitivity of an estimate without repairing the prespecified test. Post-randomization exclusions may break comparability, particularly when selected after outcomes are known. The primary effect estimate, confidence interval, exact noninferiority margin and full disposition should be supplied before estimating how far the trial missed; the topline prose does not provide all of them.

Noninferiority is a confidence-bound claim, not simply a small difference in average vision. Interpretation requires assurance that the active control retained its expected effect and rescue or missing visits did not make the groups artificially similar. Conversely, calling the control unusually strong relative to other trials does not invalidate the observed randomized comparison. External trials can differ in baseline vision, disease activity and definitions of unrelated vision loss. Transparent adjudication of each major loss, including whether reviewers remained masked, would help explain the imbalance. Removing those eyes answers a conditional question; patients starting treatment cannot know that they belong to the favorable selected subset. If subsequent analyses are clinically persuasive, they may inform regulatory discussion, but their evidentiary role must remain distinct from the original prespecified full-dataset primary endpoint and its failed result.

Secondary durability and selection effects

LUGANO reported 76% supplement-free through week32 and54% through week56, with42% less treatment burden than control. These signals support further investigation, but secondary nominal p-values do not recover confirmatory status after primary failure unless the prespecified testing plan explicitly allows it. The two timepoints also cannot be turned into patient-level relapse rates without longitudinal records. [1] [3]

Selecting only supplement-free eyes conditions on a post-treatment outcome. That can preferentially retain eyes with better response or prognosis and produces a different question from the original randomized comparison. An anatomical difference of only a few microns cannot substitute for the visual-acuity endpoint that was selected to protect patients from an inferior treatment strategy.

Safety and the remaining clinical program

The release reported no observed insert migration, retinal vasculitis or severe intraocular inflammation and no difference in several ocular safety categories. Complete arm-level incidence and exposure data were not supplied in that summary. Absence of a named severe event is not evidence that all eye-related adverse outcomes were absent or that rare repeat-dose risks are excluded. [1] [5] [6]

LUCIA is the separate remaining pivotal wet-AMD trial, with Q4 2026 guidance. A positive LUCIA could add independent evidence but would not retroactively change LUGANO's prespecified outcome. Regulatory interpretation will require the combined efficacy and safety package, consistency of endpoints and sensitivity analyses; a planned 2027 filing is a management intention, not an accepted application.

Sources / References

1. EyePoint LUGANO topline release, August 17, 2026
2. EyePoint SEC 8-K, August 17, 2026
3. EyePoint original DAVIO2 results presentation
4. EyePoint DAVIO2 topline release
5. LUGANO registry NCT06668064
6. EyePoint 2024 second-quarter update: 12-month DAVIO2 follow-up